New Study Published in JAMA Supports Neurotez Plans for the Development of Leptin as a Therapy for AD
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Dec 16, 2009 - This week's issue of the Journal of the American Medical Association (Dec 16) features a report on a long-term, prospective study of elderly, dementia-free individuals led by researchers from Boston University School of Medicine and the Framingham Heart Study focusing on the association between the protein hormone Leptin and the risk of developing Alzheimer's disease (AD). Specifically, people with higher baseline circulating Leptin levels were found to have a significantly reduced incidence of AD and dementia. Individuals in the lowest quartile of gender-specific Leptin levels had an absolute AD risk of 25%, while persons in the highest quartile had only a 6% risk over a 12-year follow-up period.
Professor Mark A. Smith, Chief Scientific Officer (CSO) of Neurotez and Professor of Pathology at Case Western Reserve University stated “In support of the importance of Leptin in AD, the article quotes experimental data from Neurotez where we have shown that Leptin decreases the underlying AD pathology and improves memory function in animals.” In the article's conclusion, and citing another paper from Neurotez, the authors state, “... more importantly, (these findings) may open new pathways for possible preventive and therapeutic interventions.”
“Neurotez was not at all involved in this important study,” said Neurotez CEO Nikolaos Tezapsidis, “but the results strongly support our plans to take a Leptin product into clinical trials as a novel hormone replacement therapy for AD.”
Comments from Dr. J. Wesson Ashford, MD, PhD (Stanford/VA Aging Clinical Research Center in Stanford, Calif.) who is leading the Neurotez trial and is co-investigator in an SBIR grant to Neurotez can be found in an interview at WebMD published yesterday: http://www.webmd.com/alzheimers/news/20091215/more-leptin-may-mean-less-alzheimers
AD represents a major unmet medical need, with current medicines providing only limited symptomatic relief, representing a global market of $5 billion.
Neurotez, Inc. will provide an update to the investment community of the company's clinical and business development plans at the Biotech Showcase 2010 meeting in San Francisco. The Biotech Showcase™ will take place at the Marines' Memorial Club & Hotel on January 12-13, 2010. http://www.ebdgroup.com/bts/
About Neurotez, Inc.
Neurotez Inc., founded in 2005, is a privately held Delaware corporation operating from New Jersey, formed to launch the clinical development of Leptin as a hormone replacement therapy for Alzheimer's disease, and as a preventative remedy for those at risk. Neurotez currently uses biochemistry, molecular and cell biology along with in vivo models to discover and develop biopharmaceuticals for central nervous system disorders. Neurotez aims to continue to focus on programs with a potential for high impact in healthcare while building a fully-integrated platform that spans activities from discovery to proof of concept clinical trials.
To find out more, please visit www.neurotez.com.
Contact: Neurotez Inc.
Jane Johnston, PhD, 732-729-6250 x 4702
Posted: December 2009